Literature DB >> 23716549

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.

Zdenek Racil1, Filip Razga, Jana Drapalova, Lucie Buresova, Daniela Zackova, Martina Palackova, Lukas Semerad, Ludmila Malaskova, Martin Haluzik, Jiri Mayer.   

Abstract

Entities:  

Keywords:  glucose metabolism; nilotinib; tyrosin kinase inhibitor

Mesh：

Substances：

Year:  2013        PMID： 23716549      PMCID： PMC3789473          DOI： 10.3324/haematol.2013.086355

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures.

Authors:  M Gutt; C L Davis; S B Spitzer; M M Llabre; M Kumar; E M Czarnecki; N Schneiderman; J S Skyler; J B Marks
Journal:  Diabetes Res Clin Pract       Date:  2000-03       Impact factor: 5.602

2.  Surrogate markers of insulin resistance: A review.

Authors:  Bhawna Singh; Alpana Saxena
Journal:  World J Diabetes       Date:  2010-05-15

3.  Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study.

Authors:  Aimin Xu; Annette W K Tso; Bernard M Y Cheung; Yu Wang; Nelson M S Wat; Carol H Y Fong; Dennis C Y Yeung; Edward D Janus; Pak C Sham; Karen S L Lam
Journal:  Circulation       Date:  2007-03-27       Impact factor: 29.690

Review 4.  Update on incretin hormones.

Authors:  Liza K Phillips; Johannes B Prins
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

Review 5.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.

Authors:  R A DeFronzo
Journal:  Diabetologia       Date:  2010-04-02       Impact factor: 10.122

Review 6.  Diabetes and cancer.

Authors:  Paolo Vigneri; Francesco Frasca; Laura Sciacca; Giuseppe Pandini; Riccardo Vigneri
Journal:  Endocr Relat Cancer       Date:  2009-07-20       Impact factor: 5.678

7.  Association of hypoadiponectinemia with coronary artery disease in men.

Authors:  Masahiro Kumada; Shinji Kihara; Satoru Sumitsuji; Toshiharu Kawamoto; Satoru Matsumoto; Noriyuki Ouchi; Yukio Arita; Yoshihisa Okamoto; Iichiro Shimomura; Hisatoyo Hiraoka; Tadashi Nakamura; Tohru Funahashi; Yuji Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311

Review 8.  c-Abl and insulin receptor signalling.

Authors:  Marco Genua; Giuseppe Pandini; Maria Francesca Cassarino; Rosa Linda Messina; Francesco Frasca
Journal:  Vitam Horm       Date:  2009       Impact factor: 3.421

9.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

10.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047
View more
  22 in total

Review 1.  Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Authors:  Peter Valent; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang Füreder; Gerit-Holger Schernthaner; Wolfgang R Sperr; Rudolf Kirchmair; Dominik Wolf
Journal:  Leuk Res       Date:  2017-05-12       Impact factor: 3.156

Review 2.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

Review 3.  From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors:  Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal:  Antioxid Redox Signal       Date:  2017-05-15       Impact factor: 8.401

4.  Dasatinib-induced chylothorax: An unusual presentation of a common adverse event-A case report with literature review.

Authors:  Theresa Paul; Anil Yousaf Ellahie; Yazan Salah Almohtasib; Urshita Sinha; Halima El Omri
Journal:  EJHaem       Date:  2021-05-18

5.  Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.

Authors:  Naoto Okada; Takahiro Niimura; Yoshito Zamami; Hirofumi Hamano; Shunsuke Ishida; Mitsuhiro Goda; Kenshi Takechi; Masayuki Chuma; Masaki Imanishi; Keisuke Ishizawa
Journal:  Cancer Med       Date:  2018-12-18       Impact factor: 4.452

6.  Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.

Authors:  Tomohiko Ozaki; Hajime Nakamura; Nobuyuki Izutsu; Hiroaki Masaie; Jun Ishikawa; Manabu Kinoshita
Journal:  Interv Neuroradiol       Date:  2017-06-05       Impact factor: 1.610

7.  Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients.

Authors:  Gaëlle Fossard; Emilie Blond; Marie Balsat; Stéphane Morisset; Stéphane Giraudier; Martine Escoffre-Barbe; Hélène Labussière-Wallet; Maël Heiblig; Arthur Bert; Madeleine Etienne; Jocelyne Drai; Mohamad Sobh; Isabelle Redonnet-Vernhet; Jean-Christophe Lega; François-Xavier Mahon; Gabriel Etienne; Franck Emmanuel Nicolini
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

8.  Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.

Authors:  D Rea; T Mirault; E Raffoux; N Boissel; A L Andreoli; P Rousselot; H Dombret; E Messas
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

9.  Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion.

Authors:  A Maurizot; J-P Beressi; B Manéglier; N H de la Marre; M Spentchian; P Soury; P Solvet-Sebire; C Collet-Gaudillat; J-M Baud; B Livarek; F Guilhot; P Rousselot
Journal:  Blood Cancer J       Date:  2014-09-19       Impact factor: 11.037

10.  Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.

Authors:  Delphine Rea; Tristan Mirault; Thomas Cluzeau; Jean-François Gautier; François Guilhot; Hervé Dombret; Emmanuel Messas
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.